Sales in the clinical diagnostics market are estimated at $25 billion and growing at approximately 7% annually. The industry is dominated by a broad range of serum and plasma products, ranging from blood glucose levels to prostate cancer, to osteoporosis.
Tests are performed in a variety of ways from simple 1-step rapid tests to complex laboratory equipment. Testing is performed in hospitals, clinics, physicians' offices as well as patient's homes. Recent trends in the market indicate a shift toward Point of Care/Contact Testing (POCT) using rapid immunoassay technologies.
POCT provides the benefits of a quick result that is both accurate and inexpensive. It is generally accepted that successful treatment is highly dependant on a timely diagnosis. POCT provides easy access to diagnostics, which encourages early diagnosis and treatment.
Avitar is a leader in oral fluid diagnostics. Using our proprietary polyurethane foam to successfully introduce ORALscreen, the world's first rapid POCT test for drugs of abuse using oral fluid, we have established our presence as the industry leader in oral fluid diagnostics. Several patents have been issued and additional patents are pending which will ensure our position in the field. Our goal is to extend this expertise into the in-vitro, clinical diagnostic marketplace.
Avitar estimates that 80-85% of the diagnostics performed today can be adapted to oral fluid technology. We continue to evaluate the marketplace for opportunities in in-vitro diagnostics.
Please continue to visit our site for continuing developments and updates to the Avitar oral fluid products.